Amor M. Srikureja

机构：Sarcoma Oncology Center

发表论文 5 篇 · 总被引 55 次 · h-index 3

代表论文

SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma (2023 · Cancers · 被引 38)
SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma. (2019 · Journal of Clinical Oncology · 被引 9)
Long Term Survival Following DeltaRex-G/DeltaVax Tumor-Targeted Gene Therapy for Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone (2021 · Clinics in Oncology · 被引 6)
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma. (2019 · Journal of Clinical Oncology · 被引 2)
SAINT: A Phase II/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma (2022 · SSRN Electronic Journal)